Technology | January 20, 2010

First MRA Contrast Agent for AIOD Enters U.S. Market

Ablavar has an MRA indication to evaluate aortoiliac occlusive disease.

January 20, 2010 - The first FDA-cleared contrast imaging agent for use with a magnetic resonance angiography (MRA) indication to evaluate aortoiliac occlusive disease (AIOD) and suspected peripheral vascular disease enters the U.S. market today.

AIOD is a type of peripheral vascular disease that occurs when arteries, which carry blood from the heart to the lower limbs, become narrowed or blocked. This lack of blood supply can result in pain, infection and even loss of limbs[i]. 
 
In Phase 3 clinical studies, Ablavar, the contrast agent that Lantheus Medical Imaging launched today, demonstrated statistically greater sensitivity (detecting disease when present) compared with noncontrast MRA[ii]. These studies, which supported the U.S. Food and Drug Administration (FDA) approval of Ablavar, show that MRA images using Ablavar provided diagnostic accuracy comparable to conventional X-ray angiography,[iii],[iv] an invasive procedure which involves insertion of a catheter into the arteries in the upper thigh (groin area) or arm[v].
 
“Ablavar provides distinct advantages over X-ray angiography, the current standard of care in diagnosing AIOD,” said Mark G. Hibberd, M.D., Ph.D., senior medical director, Global Medical Affairs, Lantheus Medical Imaging, Inc. “Ablavar provides high resolution images comparable to conventional X-ray angiography (the current gold standard), which offers radiologists a clear, enhanced visualization of patients’ arteries. However, Ablavar is given in a single, low dose injection, does not require catheter insertion into a patient’s arteries, and does not expose patients to ionizing radiation, all of which are tangible benefits to patients.”

According to E. Kent Yucel, M.D., FACR, chairman of radiology, Tufts Medical Center, the new contrast agent "may provide clinicians performing vascular imaging with more comprehensive, three-dimensional diagnostic information to improve patient treatment decisions and care."

The introduction of the MRA imaging agent extends Lantheus Medical's product portfolio in the radiology and peripheral vascular disease markets and adds to its diagnostic imaging agents for MRI, SPECT, PET and echocardiography imaging modalities.

Ablavar is approved in 37 countries outside the United States and has been used in nearly 90,000 patients to date.
Contraindications: History of a prior allergic reaction to a gadolinium-based contrast agent. Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate

References:
[i] Vascular Web. Society for Vascular Surgery. "Aortoiliac Occulsive Disease." http://www.vascularweb.org/patients/NorthPoint/Aortoiliac_Occlusive_Dise.... Assessed Oct. 26, 2009.
[ii] Data on file, Lantheus Medical Imaging Inc.
[iii] Goyen M, Edelman M, Perreault P, et al. "MR Angiography of Aortoiliac Occulsive Disease: A Phase III Study of the Safety and Effectiveness of the Blood-Pool Contrast Agent MS-325." Radiology. 2005; 236(3):825-833.
[iv] Rapp JH, Wolff SD, Quinn SF, et al. "Aortoiliac Occulsive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-Enhanced MR Angiography – Multicenter Comparative Phase III Study." Radiology. 2005; 236(1):71-78.
[v] American Heart Association. "What is Coronary Angiography?" http://www.americanheart.org/presenter.jhtml?identifier=11222. Assessed on Oct. 26, 2009.
[vi] The Imaging Market Guide (U.S. Edition 2009), Arlington Medical Resources Inc. Malvern, Pa..
[vii] National Heart, Lung, and Blood Institute. National Institutes of Health. "Other Names for Peripheral Arterial Disease." http://www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_onames.html. Assessed March 30, 2009.
[viii] National Heart, Lung, and Blood Institute. National Institutes of Health. "Who Is At Risk for Peripheral Arterial Disease?" http://www.nhlbi.nih.gov/health/dci/Diseases/pad/pad_risk.html. Assessed March 30, 2009.

For more information: www.ablavar.com and www.lantheus.com

Related Content

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Image courtesy of Philips

Image courtesy of Philips

Feature | Interventional Radiology | July 05, 2018 | By Jeff Zagoudis
On May 14, 2018, First Lady Melania Trump underwent an embolization procedure for what was called a benign kidney...
Embolx Announces FDA Clearance of Next-generation Sniper Balloon Occlusion Microcatheter
Technology | Interventional Radiology | June 29, 2018
Embolx Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation...
Guerbet Launches Pair of Microcatheters for Interventional Radiology Procedures
Technology | Interventional Radiology | May 23, 2018
Guerbet LLC USA announced the upcoming launch of SeQure and DraKon, two novel microcatheters for tumor and vascular...
Melania Trump in hospital to undergo an interventional radiology (IR) catheter embolization procedure in her kidneys. Angiogram of a kidney.

First Lady Melania Trump in hospital to undergo an interventional radiology (IR) catheter embolization procedure in her kidneys. The left image is an example of a kidney angiogram to highlight the renal blood vessels during an interventional procedure.

News | Interventional Radiology | May 15, 2018 | Dave Fornell
May 15, 2018 — U.S.
Overlay Init